Insider Trading Alert - OXFD, CSWC And CVS Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 2, 2015, 108 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $118.41 to $55,354,995.00.

Highlighted Stocks Traded by Insiders:

Oxford Immunotec Global (OXFD) - FREE Research Report

Sandberg Richard A, who is Director at Oxford Immunotec Global, sold 3,000 shares at $14.14 on June 2, 2015. Following this transaction, the Director owned 45,174 shares meaning that the stake was reduced by 6.23% with the 3,000-share transaction.

The shares most recently traded at $14.35, up $0.21, or 1.48% since the insider transaction. Historical insider transactions for Oxford Immunotec Global go as follows:

  • 4-Week # shares sold: 53,415
  • 12-Week # shares sold: 207,734
  • 24-Week # shares sold: 210,734

The average volume for Oxford Immunotec Global has been 49,800 shares per day over the past 30 days. Oxford Immunotec Global has a market cap of $320.8 million and is part of the health care sector and drugs industry. Shares are up 4.63% year-to-date as of the close of trading on Tuesday.

Oxford Immunotec Global PLC, a diagnostics company, develops and commercializes proprietary tests for the management of immune-regulated conditions in the United States, Europe, Japan, and China. Currently, there are 4 analysts who rate Oxford Immunotec Global a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OXFD - FREE

TheStreet Quant Ratings rates Oxford Immunotec Global as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Oxford Immunotec Global Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Capital Southwest Corporation (CSWC) - FREE Research Report

Kelley Douglas M., who is Sr. VP & Managing Director at Capital Southwest Corporation, bought 14 shares at $50.35 on June 2, 2015. Following this transaction, the Sr. VP & Managing Director owned 7,014 shares meaning that the stake was boosted by 0.2% with the 14-share transaction.

The shares most recently traded at $49.68, down $0.67, or 1.34% since the insider transaction. Historical insider transactions for Capital Southwest Corporation go as follows:

  • 4-Week # shares bought: 2,375
  • 4-Week # shares sold: 2,000
  • 12-Week # shares bought: 2,375
  • 12-Week # shares sold: 2,000
  • 24-Week # shares bought: 2,895
  • 24-Week # shares sold: 2,000

The average volume for Capital Southwest Corporation has been 43,200 shares per day over the past 30 days. Capital Southwest Corporation has a market cap of $782.0 million and is part of the financial sector and financial services industry. Shares are up 32.71% year-to-date as of the close of trading on Tuesday.

Capital Southwest Corporation is a business development company specializing in private equity investments in growth capital, acquisition financings, management buyouts, and minority recapitalizations. The stock currently has a dividend yield of 0.4%. The company has a P/E ratio of 3.9.

Exclusive Offer: Get the latest Stock Analysis on CSWC - FREE

TheStreet Quant Ratings rates Capital Southwest Corporation as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Capital Southwest Corporation Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

CVS Health (CVS) - FREE Research Report

Brown C David Ii, who is Director at CVS Health, sold 10,000 shares at $102.57 on June 2, 2015. Following this transaction, the Director owned 91,252 shares meaning that the stake was reduced by 9.88% with the 10,000-share transaction.

The shares most recently traded at $102.10, down $0.47, or 0.46% since the insider transaction. Historical insider transactions for CVS Health go as follows:

  • 4-Week # shares sold: 15,000
  • 12-Week # shares sold: 51,305
  • 24-Week # shares sold: 55,525

The average volume for CVS Health has been 4.4 million shares per day over the past 30 days. CVS Health has a market cap of $115.7 billion and is part of the health care sector and health services industry. Shares are up 5.73% year-to-date as of the close of trading on Tuesday.

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services in the United States. The company operates through Pharmacy Services and Retail Pharmacy segments. The stock currently has a dividend yield of 1.37%. The company has a P/E ratio of 25.1. Currently, there are 15 analysts who rate CVS Health a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CVS - FREE

TheStreet Quant Ratings rates CVS Health as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full CVS Health Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet